The Competition Commission of India (CCI) has approved Mankind Pharma's acquisition of Bharat Serums and Vaccines Ltd (BSV) for approximately ₹13,630 crore. Mankind secured the deal from private equity firm Advent International, surpassing bids from other competitors. This acquisition is anticipated to enhance Mankind's growth, with BSV's operations complementing its existing portfolio. In FY23-24, BSV reported ₹1,723 crore in revenue, a 20% increase with 28% EBITDA margins. Specializing in women's healthcare and emergency medicine, BSV has a presence in over 70 countries, boosting Mankind's market position.